Inactivation of Interferon Regulatory Factor-1 Tumor Suppressor Protein by HPV E7 Oncoprotein

In studying biological roles of interferon regulatory factor (IRF)-1 tumor suppressor in cervical carcinogenesis, we found that HPV E7 is functionally associated with IRF-1. Binding assays indicate a physical interaction between IRF-1 and HPV E7in vivo and in vitro. The carboxyl-terminal transactivation domain of IRF-1 was required for the interaction. Transient co-expression of E7 significantly inhibits the IRF-1-mediated activation of IFN-β promoter in NIH-3T3 cells. Co-transfection of E7 mutants reveals that the pRb-binding portion of E7 is necessary for the E7-mediated inactivation of IRF-1. It was next determined whether histone deacetylase (HDAC) is involved in the inactivation mechanism as recently suggested, where the carboxyl-terminal zinc finger domain of E7 associates with NURD complex containing HDAC. When trichostatin A, an inhibitor of HDAC, was treated, the repressing activity of E7 was released in a dose-dependent manner. Furthermore, the mutation of zinc finger abrogates such activity without effect on the interaction with IRF-1. These results suggest that HPV E7 interferes with the transactivation function of IRF-1 by recruiting HDAC to the promoter. The immune-promoting role of IRF-1 evokes the idea that our novel finding might be important for the elucidation of the E7-mediated immune evading mechanism that is frequently found in cervical cancer.

[1]  P. Chambon,et al.  Activation function 2 (AF‐2) of retinoic acid receptor and 9‐cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF‐2 activity. , 1994, The EMBO journal.

[2]  D. McCance,et al.  Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes , 1992, Journal of virology.

[3]  F. Rösl,et al.  Monocyte‐chemo‐attractant‐protein‐1 (mcp‐1)‐gene expression in cervical intra‐epithelial neoplasias and cervical carcinomas , 1999, International journal of cancer.

[4]  C. Hovens,et al.  An In Vitro Assay of β-Galactosidase from Yeast , 1996 .

[5]  Jonathan A. Cooper,et al.  Mammalian Ras interacts directly with the serine/threonine kinase raf , 1993, Cell.

[6]  C. Meijer,et al.  Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. , 1994, British Journal of Cancer.

[7]  G. Demers,et al.  Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation , 1996, Journal of virology.

[8]  H. Ploegh.  Viral strategies of immune evasion. , 1998, Science.

[9]  R. Ransohoff,et al.  IFN-γ Induction of the Human Monocyte Chemoattractant Protein (hMCP)-1 Gene in Astrocytoma Cells: Functional Interaction Between an IFN-γ-Activated Site and a GC-Rich Element , 1998, The Journal of Immunology.

[10]  Gerald R. Fink,et al.  Methods in Yeast Genetics: A Laboratory Course Manual , 1987 .

[11]  N. Webster,et al.  The human estrogen receptor has two independent nonacidic transcriptional activation functions , 1989, Cell.

[12]  V. Garsky,et al.  Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein , 1993, Molecular and cellular biology.

[13]  H. Pfister.  Human papillomaviruses and genital cancer. , 1987, Advances in cancer research.

[14]  Andrew J. Bannister,et al.  The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth , 1999, The EMBO journal.

[15]  Soldano Ferrone,et al.  Different Requirements for Signal Transducer and Activator of Transcription 1α and Interferon Regulatory Factor 1 in the Regulation of Low Molecular Mass Polypeptide 2 and Transporter Associated with Antigen Processing 1 Gene Expression* , 1998, The Journal of Biological Chemistry.

[16]  Ronald N. Germain,et al.  MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation , 1994, Cell.

[17]  T. Maniatis,et al.  Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. , 1998, Molecular cell.

[18]  G. Blair,et al.  The MHC‐encoded TAP1/LMP2 bidirectional promoter is down‐regulated in highly oncogenic adenovirus type 12 transformed cells , 1997, FEBS letters.

[19]  S. Riethdorf,et al.  Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. , 1996, The American journal of pathology.

[20]  B. Rollins,et al.  Suppression of tumor formation in vivo by expression of the JE gene in malignant cells , 1991, Molecular and cellular biology.

[21]  P. Jansen-Dürr.  How viral oncogenes make the cell cycle. , 1996, Trends in genetics : TIG.

[22]  P. Chambon,et al.  The yeast Ada complex mediates the ligand-dependent activation function AF-2 of retinoid X and estrogen receptors. , 1998, Genes & development.

[23]  W. Min,et al.  Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. , 1996, Journal of immunology.

[24]  P. Halloran,et al.  IFN regulatory factor-1 plays a central role in the regulation of the expression of class I and II MHC genes in vivo. , 1997, Journal of immunology.

[25]  A. J. Valente,et al.  A complex element regulates IFN-gamma-stimulated monocyte chemoattractant protein-1 gene transcription. , 1998, Journal of immunology.

[26]  E. Androphy,et al.  Cellular transformation by papilomavirus oncorproteins , 1993 .

[27]  P. Chambon,et al.  Retinoic Acid Receptors Interact Physically and Functionally with the T:G Mismatch-specific Thymine-DNA Glycosylase* , 1998, The Journal of Biological Chemistry.

[28]  K. Münger,et al.  A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. , 1994, Virology.

[29]  Fred Winston,et al.  Methods in Yeast Genetics: A Laboratory Course Manual , 1990 .

[30]  L. Gissmann,et al.  E7-specific cytotoxic T cell tolerance in HPV-transgenic mice , 1999, Archives of Virology.

[31]  N. McMillan,et al.  The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-alpha. , 1999, Virology.

[32]  P. Chambon,et al.  A new version of the two-hybrid assay for detection of protein-protein interactions. , 1995, Nucleic acids research.

[33]  C. Meijer,et al.  Analysis of MHC class I and II expression in relation to presence of HPV genotypes in premalignant and malignant cervical lesions. , 1993, British Journal of Cancer.

[34]  M. Vidal,et al.  Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. , 1998, Genes & development.

[35]  J. Bos,et al.  Adenovirus E1A represses transcription of the cellular JE gene , 1989, Journal of virology.

[36]  T. Taniguchi,et al.  Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1 , 1994, Cell.

[37]  F. Schaper,et al.  Interferon regulatory factor 1 (IRF-1) mediates cell growth inhibition by transactivation of downstream target genes. , 1993, Nucleic acids research.

[38]  P. Moore,et al.  Regulation of Type I Interferon Gene Expression by Interferon Regulatory Factor-3* , 1998, The Journal of Biological Chemistry.